A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.

Azad, Nilofer; Perroy, Alyssa; Gardner, Erin; Imamura, Chiyo K; Graves, Cynthia; Sarosy, Gisele A; Minasian, Lori; Kotz, Herbert; Raggio, Miranda; Figg, William D; Kohn, Elise C

Azad, Nilofer; Perroy, Alyssa; Gardner, Erin; Imamura, Chiyo K; Graves, Cynthia; Sarosy, Gisele A; Minasian, Lori; Kotz, Herbert; Raggio, Miranda; Figg, William D; Kohn, Elise C.

Affiliation

Azad N; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. nazad2@jhmi.edu

Cancer Biol Ther ; 8(19): 1800-5, 2009 Oct.

Article in En | MEDLINE | ID: mdl-19738417

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Neoplasms/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms/metabolism; Neoplasms/pathology; Paclitaxel/administration & dosage; Treatment Outcome; Triazoles/administration & dosage; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Biol Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2009 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google